Jump to content
RemedySpot.com

Pharmasset Initiates Dosing In A Combination Study Of PSI-7977 And PSI-938 For Chronic Hepatitis C

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 10

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

Pharmasset, Inc. (Nasdaq: VRUS) announced that dosing has begun in

Part 2 of a Phase 1 study. This is the first clinical study

combining a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide

analog for HCV, and is designed to evaluate once daily doses of

PSI-7977 and PSI-938 in patients with HCV who have not been treated

previously.

For full news release, go to

http://www.medicalnewstoday.com/articles/209703.php?nfid=83211

--

Bill Eastman

www.ke5asu.com/links.html

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...